These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
303 related items for PubMed ID: 8866667
1. Variants of the human prostate LNCaP cell line as tools to study discrete components of the androgen-mediated proliferative response. Soto AM, Lin TM, Sakabe K, Olea N, Damassa DA, Sonnenschein C. Oncol Res; 1995; 7(10-11):545-58. PubMed ID: 8866667 [Abstract] [Full Text] [Related]
2. Androgens stimulate fatty acid synthase in the human prostate cancer cell line LNCaP. Swinnen JV, Esquenet M, Goossens K, Heyns W, Verhoeven G. Cancer Res; 1997 Mar 15; 57(6):1086-90. PubMed ID: 9067276 [Abstract] [Full Text] [Related]
3. Differentially expressed genes in androgen-dependent and -independent prostate carcinomas. Chang GT, Blok LJ, Steenbeek M, Veldscholte J, van Weerden WM, van Steenbrugge GJ, Brinkmann AO. Cancer Res; 1997 Sep 15; 57(18):4075-81. PubMed ID: 9307296 [Abstract] [Full Text] [Related]
4. Prostate cancer cells (LNCaP) generated after long-term interleukin 6 (IL-6) treatment express IL-6 and acquire an IL-6 partially resistant phenotype. Hobisch A, Ramoner R, Fuchs D, Godoy-Tundidor S, Bartsch G, Klocker H, Culig Z. Clin Cancer Res; 2001 Sep 15; 7(9):2941-8. PubMed ID: 11555613 [Abstract] [Full Text] [Related]
5. Negative controls of cell proliferation: human prostate cancer cells and androgens. Sonnenschein C, Olea N, Pasanen ME, Soto AM. Cancer Res; 1989 Jul 01; 49(13):3474-81. PubMed ID: 2731169 [Abstract] [Full Text] [Related]
6. The TRPS1 transcription factor: androgenic regulation in prostate cancer and high expression in breast cancer. Chang GT, Jhamai M, van Weerden WM, Jenster G, Brinkmann AO. Endocr Relat Cancer; 2004 Dec 01; 11(4):815-22. PubMed ID: 15613454 [Abstract] [Full Text] [Related]
7. Androgen and taxol cause cell type-specific alterations of centrosome and DNA organization in androgen-responsive LNCaP and androgen-independent DU145 prostate cancer cells. Schatten H, Ripple M, Balczon R, Weindruch R, Chakrabarti A, Taylor M, Hueser CN. J Cell Biochem; 2000 Jan 01; 76(3):463-77. PubMed ID: 10649443 [Abstract] [Full Text] [Related]
8. Androgen receptor stabilization in recurrent prostate cancer is associated with hypersensitivity to low androgen. Gregory CW, Johnson RT, Mohler JL, French FS, Wilson EM. Cancer Res; 2001 Apr 01; 61(7):2892-8. PubMed ID: 11306464 [Abstract] [Full Text] [Related]
9. Switch from antagonist to agonist of the androgen receptor bicalutamide is associated with prostate tumour progression in a new model system. Culig Z, Hoffmann J, Erdel M, Eder IE, Hobisch A, Hittmair A, Bartsch G, Utermann G, Schneider MR, Parczyk K, Klocker H. Br J Cancer; 1999 Sep 01; 81(2):242-51. PubMed ID: 10496349 [Abstract] [Full Text] [Related]
16. Androgen receptor signaling and vitamin D receptor action in prostate cancer cells. Murthy S, Agoulnik IU, Weigel NL. Prostate; 2005 Sep 01; 64(4):362-72. PubMed ID: 15754350 [Abstract] [Full Text] [Related]
17. Butyrate analogue, isobutyramide, inhibits tumor growth and time to androgen-independent progression in the human prostate LNCaP tumor model. Gleave ME, Sato N, Sadar M, Yago V, Bruchovsky N, Sullivan L. J Cell Biochem; 1998 Jun 01; 69(3):271-81. PubMed ID: 9581866 [Abstract] [Full Text] [Related]